Please login to the form below

Not currently logged in
Email:
Password:

CMPT announces CEO and loan investment

CMP Therapeutics has announced that Dr Neill Moray Mackenzie will become CEO and that the company will receive a €1.5m convertible loan investment

CMP Therapeutics (CMPT) has appointed Dr Neill Moray Mackenzie to the role of CEO, replacing Dr Bruce Savage, who leaves CMPT to concentrate on his other portfolio companies.

Dr Mackenzie brings to CMPT experience at executive board level in both the biotechnology and pharmaceutical industries. He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji (London).

Dr MacKenzie was also a departmental head in vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

In addition, CMPT has announced that the company will receive an injection of €1.5m in the form of a convertible loan from Inventages Venture Capital, which will be used to support continuing operations and the upcoming clinical trial of its lead product for the common cold.

Since 2005 CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures.

2nd August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....